Medical Doctor Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Chih-Chun Lin

Neurology New York, NY Medical Doctor

NPI 1366837668 CMS profile 6728447

710 W 168Th St, Ni 3-313, New York, NY 10032

Open in the dashboard

General payments

$46,838

25 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$36,299 paid to institutions, not to them · program years 2024–2025

Through program year 2023, Chih-Chun Lin of New York, NY is reported in the CMS Open Payments database as having received $46,838 across 25 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $36,299 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 89th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $1,462 5
2022 General $29 2
2020 General $20,077 2
2019 General $25,269 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Chih-Chun Lin
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Chih-Chun Lin were reported at $0. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Chih-Chun Lin Neurology median Middle half National median
2019 $25,269 $474 $118–$2,177 $163
2020 $20,077 $367 $82–$2,309 $114
2021 $0 $438 $104–$2,547 $132
2022 $29 $442 $103–$2,388 $149
2023 $1,462 $464 $119–$2,312 $160
2024 $0 $468 $119–$2,323 $164
2025 $0 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Medtronic USA, Inc. $35,000 2 payments
  2. Boston Scientific Corporation $10,023 2 payments
  3. Sage Therapeutics, Inc. $1,539 6 payments
  4. Genzyme Corporation $80 4 payments
  5. Avanir Pharmaceuticals, Inc. $54 3 payments
  6. Acorda Therapeutics, Inc $45 2 payments
  7. Genentech USA, Inc. $31 2 payments
  8. ACADIA Pharmaceuticals Inc $29 2 payments
  9. Amgen Inc. $20 1 payment
  10. Janssen Pharmaceuticals, Inc $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Grant $45,000 3 payments
  2. Travel and Lodging $1,014 2 payments
  3. Food and Beverage $779 18 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $45 2 payments
Products named General payments · program years 2019–2023
  1. ACTIVA $35,000 2 payments
  2. VERCISE $10,000 1 payment
  3. AUBAGIO $80 4 payments
  4. NUEDEXTA $54 3 payments
  5. INBRIJA $45 2 payments
  6. Activase $31 2 payments
  7. NUPLAZID $29 2 payments
  8. WATCHMAN $23 1 payment
  9. Repatha $20 1 payment
  10. XARELTO $17 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

48

Median for Neurology: 833

Drug cost

$180,702

Median for Neurology: $202,670

Branded share of claims

100%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 19 $179,858
Carbidopa-Levodopa Carbidopa/Levodopa Brand 29 $844

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$7,659

Medicare's payments for the services billed

Medicare patients

24

Average age 72

Services billed

122

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

25 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record